Person Centered Care Case Study

Figure 2. A descriptive observation of use of antipsychotic and Alternative therapies, a 2-year data at the Blue Care Aged care facility and the evidence that the evaluation of the antipsychotic program is effective in providing person centered care and helped in reducing the use of antipsychotic medication with alternative therapies, (APM) antipsychotic medication, (PCC) Person Centered Care.

Discussion with Board
Priorities for action: Information and communications technology solutions to be introduced into the residential aged care system in order to improve the effectiveness and efficiency of aged care
Benefits: The benefits include an improvement in documentation efficiency, less time for documentation, staffs to have better information
Benefits: The consequences are that people will receive excellent care, it will also reduce staff distress and resolve management dilemmas, by recognizing the fundamental unsatisfiable need or cause, thus training and building talents are of paramount importance for upliftment of staff morale, staff retention, sustainability, and good practice. With a modest extra investment, the productive efficiency will help to maximize outcomes for a given cost.

Priorities for action: We can make these positive changes with modest increases in investment coupled with redesigning to the existing structure. Decisive local action should be considered using relevant data to generate goal and action planning. Change should take place ‘step by step’ and in small doses rather than change on a more radical scale. Impacts on staff will be mixed but generally improvements in
In addition facility factors such as staffing levels, nurses beliefs interdisciplinary communications and the availability of residents activities contribute to the prescribing culture. This could be helpful in trying to reduce antipsychotic drug use and stimulate the use of psychosocial alternative interventions. However, until new preventive or disease-altering medications are approved, physicians must optimize the use of available pharmaceutical and behavioral therapies. As more is learned about the combinatorial effects of these and other potential therapeutic options at all stages of dementia, the ability to significantly impact disease progression may one day be